CRISPR, Vertex say FDA granted rolling review to experimental CRISPR therapy

CRISPR Therapeutics Inc. /zigman2/quotes/201181046/composite CRSP -0.77% and Vertex Pharmaceuticals Inc. /zigman2/quotes/202259802/composite VRTX -1.35% said Tuesday that the Food and Drug Administration granted a rolling review to the exagamglogene autotemcel, the therapy the companies are developing to treat sickle cell disease and transfusion-dependent beta thalassemia. CRISPR's stock was up 3.1% in premarket trading on Tuesday, while Vertex shares gained 1.1%. Vertex said it plans to a submit an application to the FDA in November, with plans to complete the submission in the first quarter of next year. "We continue to work with urgency to bring forward the first CRISPR therapy for a genetic disease," Nia Tatsis, Vertex's chief regulatory and quality office, said in a news release. CRISPR's stock is down 19.3%, while Vertex's stock has jumped 26.0% this year. The S&P 500 /zigman2/quotes/210599714/realtime SPX -0.27% has declined 23.3% so far in 2022.

/zigman2/quotes/201181046/composite

Add to watchlist CRSP

CRISPR Therapeutics AG

US : U.S.: Nasdaq

$ 45.39

-0.35 -0.77%

Volume: 845,714

Sept. 29, 2023 4:00p

P/E Ratio

N/A

Dividend Yield

N/A

Market Cap

$3.60 billion

Rev. per Employee

$371,397

/zigman2/quotes/202259802/composite

Add to watchlist VRTX

Vertex Pharmaceuticals Inc.

US : U.S.: Nasdaq

$ 347.74

-4.76 -1.35%

Volume: 896,813

Sept. 29, 2023 4:00p

P/E Ratio

26.88

Dividend Yield

N/A

Market Cap

$89.75 billion

Rev. per Employee

$1.95M

/zigman2/quotes/210599714/realtime

Add to watchlist SPX

S&P 500 Index

US : S&P US

4,288.05

-11.65 -0.27%

Volume: 0.00

Sept. 29, 2023 5:20p